product, which dictates the review center (CDER, CDRH, or both).

The first step involves determining whether your product qualifies as a combination product and identifying its primary mode of action. You can consult the FDA’s guidance document, “Combination Products: A Regulatory Overview,” which provides key insights into the classification and regulatory requirements for various product types. Compliance with sections of the Federal Food, Drug, and Cosmetic (FDCA) Act applicable to your combination product is mandatory.

Additionally, familiarize yourself with the FDA Office of Combination Products (OCP), which oversees the regulation of these products and provides information on submission processes. Understanding the uniqueness of your combination product’s framework helps in navigating the complexities that may arise during submission and approval stages.

Step 2: Prepare the Pre-Submission Meeting Request

Once the regulatory framework is clearly understood, the next step is to prepare the Pre-Submission Meeting request. The FDA recommends that sponsors submit a formal request in writing, including specific details about the proposed combination product and the purpose of the meeting. This document should outline the following:

• Contact Information: Include details of the individuals attending the meeting and their roles.
• Product Description: Provide a thorough description of the combination product, including its components (drug, device, biologic) and their interactions.
• Meeting Objectives: Detail the objectives you wish to achieve during the pre-submission meeting, such as seeking clarification on regulatory requirements or discussing proposed development plans.
• Specific Questions: Generate a list of specific questions you intend to ask to guide the discussion effectively.
• Preferred Dates: Suggest several dates for the meeting to facilitate scheduling.

The request should be submitted electronically via the FDA’s Document Control Center or through the appropriate submission portal as specified by the relevant center (CDRH or CDER). After submission, the FDA will acknowledge receipt and respond with confirmation of the meeting date or request further information if needed.

Step 3: Develop the Pre-Submission Meeting Package

Following the confirmation of the meeting date, assemble a comprehensive Pre-Submission Meeting Package. This package is vital as it includes all the relevant documentation required for the review by the FDA. Key components of the package typically include:

• Introduction: A brief introduction to the combination product, including background information relevant to its development process.
• Regulatory Information: Outline the regulatory framework, including applicable drug/device regulations and guidance documents that govern your product’s development.
• Clinical Data: If applicable, provide preliminary clinical data or studies that support the safety and effectiveness of the combination product. This section should summarize data from both the drug and device components, emphasizing their integration.
• Manufacturing Information: Include details about the manufacturing processes for the drug and device components separately, as well as the final formulation of the combination product.
• Nonclinical Studies: Summarize any nonclinical study results that demonstrate the combination product’s safety and efficacy, ensuring adherence to ICH-GCP regulations.
• Specific Questions for Discussion: Highlight the questions previously identified in the meeting request, aimed at soliciting feedback from the agency.

The package should be organized logically, facilitating easy navigation and review by FDA personnel. Aim to provide clear, concise, and data-driven supporting information, as the quality of your package will influence the outcome of the meeting.

Step 4: Conduct the Pre-Submission Meeting

On the date of the Pre-Submission Meeting, it is essential to approach the discussion professionally and sustainably. The meeting typically involves FDA officials from relevant review divisions alongside sponsor representatives. Here are best practices that should be followed:

• Preparation: Ensure all team members are well-prepared to discuss their respective areas of expertise, including clinical, manufacturing, and regulatory concerns. Conduct pre-meeting rehearsals if necessary to practice the narrative flow of the discussion.
• Documentation: Have all supportive documents readily accessible during the discussion. Taking notes during the meeting is crucial for capturing FDA feedback and recommendations.
• Engagement: Encourage open dialogue and ensure that all questions posed to the FDA are answered. If time allows, invite follow-up questions from FDA representatives to clarify any topic discussed.
• Next Steps: Before concluding, summarize the key discussion points and ask for clarification on any outstanding issues. Identify next steps for both parties and timelines to ensure effective follow-through.

Post-meeting, it is beneficial to send a thank-you email to the FDA attendees, reiterating key points discussed and confirming any action items agreed upon during the meeting.

Step 5: Compile and Submit Meeting Minutes

Following the Pre-Submission Meeting, the next step involves compiling a summary of the meeting minutes. This document is critical as it serves as an official record of all discussions, commitments made, and feedback received from the FDA. The meeting minutes should include:

• Date and Time of Meeting: Indicate the exact date and time of the meeting for reference.
• Attendees: List all attendees from both the sponsor and FDA, including their titles and affiliations.
• Key Discussion Points: Summarize topics discussed, including any issues raised by FDA and responses provided by your team.
• Action Items: Document all action items with specified timelines for completion, assigning responsibilities for follow-up.
• Next Steps: Clearly outline the next steps in pursuit of your combination product submission, which may include additional data requests or timelines for subsequent interactions.

This document should be submitted to the FDA as a formal record within 30 days of the meeting, ensuring all discussions are captured accurately for reference in the development of your combination product.

Step 6: Follow-Up and Continuation of Development Activities

After submitting the meeting minutes, continue to engage with the FDA and monitor the progress of your combination product development. Utilize the feedback garnered during the Pre-Submission Meeting to refine your ongoing research, data collection, and product design. Key actions in this step include:

• Addressing Action Items: Tackle all action items identified in the meeting minutes, ensuring they are resolved in a timely manner.
• Continued Dialogue: Maintain open lines of communication with the FDA following up on any outstanding issues or queries related to the combination product.
• Documentation Preparedness: As you proceed to formal submissions (273 or 510(k), PMA, NDA, or BLA), keep your regulatory documentation organized and updated to reflect any changes in product design or regulatory strategy.
• Engaging Consultants: For comprehensive assistance, consider leveraging FDA combination product consulting services that specialize in navigation through complex regulatory pathways.

This phase sets the foundation for a successful submission once the intended timeline for market entry approaches. Engaging thoroughly in follow-up activities enhances your readiness for a formal request.

Step 7: Prepare for Formal Submission

The culmination of successful Pre-Submission activities leads to the formal submission of your combination product to the FDA. Depending on the classification of your product, this could involve various submission pathways such as a Premarket Approval (PMA), 510(k), New Drug Application (NDA), or Biologics License Application (BLA). To prepare for this submission ensure the following:

• Consolidation of Data: Consolidate all clinical, nonclinical, and manufacturing data compiled throughout product development into submission-ready formats as stipulated by the FDA.
• Regulatory Forms: Complete all necessary FDA forms relevant to your submission, ensuring they comply with current guidelines and submission software requirements.
• Quality Control Review: Conduct a formal quality control review of submission materials to identify any inconsistencies, ensuring content is complete and accurate, reducing the likelihood of request for additional information (RAI).
• Submission Tracking: After submission, use the FDA’s submission tracking systems to monitor the status, engaging with the agency proactively if clarifications or additional information is requested.

Ultimately, this stage is critical, as it represents the transition from development to regulatory review, setting the stage for final approval.

Step 8: Post-Approval Responsibilities

Upon receipt of marketing approval for your combination product, compliance and post-marketing responsibilities begin. Familiarize yourself with the FDA’s post-marketing surveillance requirements, including any commitments made during the submission process, which may include:

• Post-Market Clinical Studies: If stipulated, plan and conduct any required studies in compliance with FDA mandates to monitor long-term safety and effectiveness.
• Adverse Event Reporting: Implement a system for tracking and reporting adverse events as dictated by FDA regulations to maintain product integrity and patient safety.
• Continuous Risk Assessment: Engage in ongoing risk assessment initiatives to proactively manage potential safety and effectiveness issues in the product lifecycle.
• Periodic Reports: Prepare and submit periodic reports to the FDA as required, providing updates on safety, efficacy, and any change in marketing practices.

Completing this step successfully, coupled with stringent adherence to post-approval requirements, protects the product’s market presence and assures public health safety.